Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

ZVRA has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Guggenheim initiated coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Buy” and a consensus price target of $21.57.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $7.86 on Wednesday. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The firm has a fifty day simple moving average of $8.58 and a 200 day simple moving average of $7.92. The stock has a market capitalization of $419.57 million, a price-to-earnings ratio of -3.99 and a beta of 2.01. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the prior year, the business earned ($0.40) EPS. Research analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of ZVRA. FMR LLC increased its position in Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the period. Stonepine Capital Management LLC bought a new position in Zevra Therapeutics during the third quarter worth about $4,858,000. Vestal Point Capital LP bought a new position in Zevra Therapeutics in the 3rd quarter valued at about $3,644,000. Propel Bio Management LLC bought a new position in Zevra Therapeutics in the 3rd quarter valued at about $1,248,000. Finally, Geode Capital Management LLC increased its holdings in Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after buying an additional 129,600 shares during the period. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.